Moncef Slaoui has stepped down from positions at three more companies, shortly after being dismissed from a firm owned by GlaxoSmithKline for alleged sexual harassment.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh